It’s not that the TGA are not passing it’s just that they need something special to justify earlier “provisional” approval and without a Phase 3. They will happily pass later on like FDA and EMA if there was no DMOAD post a successful phase 3 pass.
I still think the TGA should not need DMOAD given the special access history and results and safety data to date. But I suppose the TGA is just like the FDA and they require stringent data before approving anything in such a big indication effecting so many.
Ann: Global Market Research indicates price for Zilosu, page-54
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 21.0¢ | 19.5¢ | $80.51K | 398.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 112938 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 4396 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |